Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

3-MeO-PCP

From PsychonautWiki Archive
Revision as of 00:57, 4 November 2015 by >Josikins
Jump to navigation Jump to search
3-MeO-PCP
Chemical Nomenclature
Common names 3-MeO-PCP, 3-MeO
Substitutive name 3-Methoxyphencyclidine
Systematic name 1-[1-(3-Methoxyphenyl)cyclohexyl]-piperidine
Class Membership
Psychoactive class Dissociative
Chemical class Arylcyclohexylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.


Smoked
Dosage
Threshold 2 mg
Light 5 - 10 mg
Common 10 - 20 mg
Strong 20 - 25 mg
Heavy 25 mg + Heavy doses may result in psychosis and mania.[1]
Duration
Total 45 - 120 minutes
Oral
Dosage
Threshold 2 mg
Light 4 - 8 mg
Common 8 - 15 mg
Strong 15 - 25 mg
Heavy 25 mg + Heavy doses may result in psychosis and mania.[1]
Duration
Total 4 - 8 hours
Onset 30 - 90 minutes
Come up 45 - 120 minutes
Peak 2 - 3 hours
Offset 1 - 2 hours
After effects 4 - 48 hours



Insufflated
Dosage
Threshold 1 mg
Light 2 - 5 mg
Common 5 - 10 mg
Strong 10 - 15 mg
Heavy 15 mg + Heavy doses may result in psychosis and mania.[1]
Duration
Total 3 - 5 hours
Onset 5 - 30 minutes
Come up 45 - 90 minutes
Peak 1.5 - 2 hours
Offset 45 - 60 minutes
After effects 4 - 48 hours






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Stimulants
Depressants

3-MeO-PCP (3-Methoxyphencyclidine) is a chemical of the arylcyclohexylamine class which acts as a hallucinogenic dissociative.

The compound was first synthesized in 1979 to investigate the structure-activity relationship of phencyclidine derivatives. The activity of 3-MeO-PCP in humans was not described until 1999 when a chemist using the pseudonym John Q. Beagle wrote that 3-MeO-PCP was qualitatively similar to PCP with comparable potency.[2] Today it is used as a recreational drug and an entheogen, rarely sold on the streets and almost exclusively obtained as a grey area research chemical through the use of online vendors.

Chemistry

This chemistry section is incomplete.

You can help by adding to it.

Pharmacology

MXE acts as an NMDA receptor antagonist. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. NMDA receptor antagonists close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “k-hole”.

3-MeO-PCP has a Ki of 20 nM for the NMDA receptor, 216 nM for the serotonin transporter and 42 for the sigma1 receptor[3] It binds to the NMDA receptor with higher affinity than PCP and has the highest affinity of the three isomeric anisyl-substitutions, followed by 2-MeO-PCP and 4-MeO-PCP. Though 3-MeO-PCP is often described as having opioid or dopaminergic activity,[4] this supposition is contradicted by data showing 3-MeO-PCP to be a potent and selective ligand for the NMDA receptor without appreciable affinity for the µ-opioid receptor or dopamine transporter.[5][6] 3-MeO-PCP was preceded by the less potent dissociative 4-MeO-PCP and first became available as a research chemical in 2011.[7]

Subjective effects

This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Physical effects

Cognitive effects

Visual effects

Suppression

Distortions

Hallucinatory states

Auditory effects

Toxicity and harm potential

The toxicity and long-term health effects of recreational 3-MeO-PCP use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 3-MeO-PCP has very little history of human usage. Anecdotal evidence from people who have tried 3-MeO-PCP within the community confirm that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses or using it sparingly (but nothing can be completely guaranteed).

Tolerance and addiction potential

In terms of 3-MeO-PCP tolerance, similar to any other NMDA antagonist, this can take weeks to build up for some, but for others it can take merely a single night of heavy use. Once a physical tolerance to MXE has set itself in, it can often take a month or more to reset itself.

3-MeO-PCP has a fairly high potential to be abused. It does not seem to physically addictive, but can become habit-forming, meaning that it could potentially be used multiple days in a row if somebody chooses to do so. There have been multiple reports across the internet of people becoming seriously addicted daily users of this substance so serious precautions and considerations should be taken before trying this substance.

Urinary tract effects

In terms of its long-term health effects when used repeatedly and with excess for extended periods of time, 3-MeO-PCP seems to exhibit almost identical bladder and urinary tract problems to those found within ketamine, but to a lesser extent. This is because 3-MeO-PCP is far more potent than ketamine so significantly less of drug needs to be consumed. Symptoms of ketamine-induced cystitis can become extremely serious and can be described as:

  • Urinary frequency - Urinary frequency is the need to empty the bladder every few minutes.
  • Urinary urgency - This can be described as a sudden, compelling need to urinate.
  • Urinary pressure - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
  • Pelvic and bladder pain - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
  • Hematuria - Hematuria is visible blood in the urine.
  • Incontinence - This is the leakage of urine.

All of these, however, can easily be avoided by simply not using 3-MeO-PCP on a daily or even weekly basis and manually limiting one's usage of the substance.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • Stimulants - Both stimulants and dissociatives carry the risk of adverse psychological reactions like anxiety, mania, delusions and psychosis and these risks are exacerbated when the two substances are combined.
  • Depressants - Because both depress the respiratory system, this combination can result in an increased risk of suddenly falling unconscious, vomiting and choking to death from the resulting suffocation. If nausea or vomiting occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

On October 18, 2012 the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-MeO-PCP.[8]

Sweden's public health agency suggested classifying 3-MeO-PCP as hazardous substance on November 10, 2014.[9]

See also

References

  1. 1.0 1.1 1.2 3-MeO-PCP Psychosis (PsychonautWiki) | https://psychonautwiki.org/wiki/3-MeO-PCP#Toxicity_and_harm_potential
  2. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs | http://onlinelibrary.wiley.com/doi/10.1002/dta.1620/abstract
  3. Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012 | https://www.gov.uk/government/publications/advisory-council-on-the-misuse-of-drugs-acmd-methoxetamine-report-2012
  4. Interview with a ketamine chemist: or to be more precise, an arylcyclohexylamine chemist | http://www.vice.com/read/interview-with-ketamine-chemist-704-v18n2
  5. Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012 | https://www.gov.uk/government/publications/advisory-council-on-the-misuse-of-drugs-acmd-methoxetamine-report-2012
  6. The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor | http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059334
  7. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs | http://onlinelibrary.wiley.com/doi/10.1002/dta.1620/abstract
  8. Advisory Council on the Misuse of Drugs (ACMD) Methoxetamine report, 2012 | https://www.gov.uk/government/publications/advisory-council-on-the-misuse-of-drugs-acmd-methoxetamine-report-2012
  9. Cannabinoider föreslås bli klassade som hälsofarlig vara | http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/